Table 2.
Clinical characteristics of ERA patients and controls.
| Comorbidities | ERA | Controls | Test | p Value |
|---|---|---|---|---|
| Cardiopathy | 7 (13,5%) | 5 (9,6%) | Χ2= 0,377 | 0,539 |
| Diabetes mellitus | 4 (7,7%) | 3 (5,8%) | Fisher's exact test | 0,500 |
| Hypertension | 26 (50,0%) | 13 (25%) | X2= 6,933 | 0,008* |
| Hypovitaminosis D | 38 (73,1%) | 1 (1,9%) | X2= 56,164 | < 0,001* |
| Osteoporosis | 17 (32,7%) | 1 (1,9%) | X2= 17,199 | < 0,001* |
| Esophageal disease | 11 (21,2%) | 0 (0,0%) | X2= 12,301 | < 0,001* |
| Gastroenteric disease | 6 (11,5%) | 1 (1,9%) | Fisher's exact test | 0,056 |
| Lung disease | 8 (15,4%) | 0 (0,0%) | Fisher's exact test | 0,003* |
| Kidney disease | 7 (13,5%) | 1 (1,9%) | Fisher's exact test | 0,029* |
| Thyroid disease | 19 (36,5%) | 7 (13,5%) | X2= 7,385 | 0,006* |
| Neurological disease | 2 (3,8%) | 1 (1,9%) | Fisher's exact test | 0,500 |
| Raynaud disease | 0 (0,00%) | 0 (0,0%) | - | - |